AbbVie Inc (ABBV) : R. G. Niederhoffer Capital Management Inc added new position in AbbVie Inc during the most recent quarter end. The investment management firm now holds 34,800 shares of AbbVie Inc which is valued at $2,316,636 , the company said in a statement filed on Aug 2, 2016 with the SEC.AbbVie Inc makes up approximately 14.16% of R. G. Niederhoffer Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Investors Capital Advisory Services boosted its stake in ABBV in the latest quarter, The investment management firm added 806 additional shares and now holds a total of 19,416 shares of AbbVie Inc which is valued at $1,292,523. AbbVie Inc makes up approx 0.25% of Investors Capital Advisory Services’s portfolio.Dt Investment Partners boosted its stake in ABBV in the latest quarter, The investment management firm added 2,818 additional shares and now holds a total of 19,296 shares of AbbVie Inc which is valued at $1,277,974. AbbVie Inc makes up approx 0.34% of Dt Investment Partners’s portfolio.Perkins Capital Management Inc reduced its stake in ABBV by selling 1,000 shares or 5.41% in the most recent quarter. The Hedge Fund company now holds 17,475 shares of ABBV which is valued at $1,115,080. AbbVie Inc makes up approx 1.23% of Perkins Capital Management Inc’s portfolio.Carroll Financial Associates reduced its stake in ABBV by selling 14 shares or 0.36% in the most recent quarter. The Hedge Fund company now holds 3,911 shares of ABBV which is valued at $247,997. AbbVie Inc makes up approx 0.04% of Carroll Financial Associates’s portfolio.Pure Financial Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 132 additional shares and now holds a total of 10,546 shares of AbbVie Inc which is valued at $683,064. AbbVie Inc makes up approx 0.23% of Pure Financial Advisors’s portfolio.
AbbVie Inc closed down -0.2 points or -0.30% at $66.34 with 53,09,293 shares getting traded on Monday. Post opening the session at $66.38, the shares hit an intraday low of $65.75 and an intraday high of $66.67 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.